PANGAEA ONCOLOGY

Trading sesion


14/06/2019 Close

1.9200

Last price


25.17 mill. €

Capitalisation

2.13

Dif.(%)


-13.51

% Year 2019

Last Trade

Date

14/06/2019

Last

1.9200

Ref.

1.8800

Dif.(%)

2.13

Volume (Shares)

600

Turnover (€x1000)

1.15

Security

Security name

PANGAEA ONCOLOGY

Ticker

PANG

ISIN

ES0105221008

NIF

A-64353584

Shares Admitted

13.110.357

Nominal

0,02 Euros

Capital Admitted

262.207,14 Euros

Trading

Fixing

Liquidity Provider

BANKINTER, S.A.

Registered Advisor

DCM ASESORES Dirección y Consultoría de Mercados, S.L.

Auditor

DELOITTE, S.L

Address

CL/ COSO 55, 50001 ZARAGOZA

Contact

investors@panoncology.com

Historical Summary

 2016201720182019 until 14/06

Capital Admitted (thousands of euros)

212212262262

Shares (x 1,000)

10,61010,61013,11013,110

Period Close Price (euros)

3.00002.34002.22001.9200

Period Last Price (euros)

3.00002.34002.22001.9200

Period High Price (euros)

3.00003.50002.46002.2000

Period Low Price (euros)

2.83002.31002.02001.8800

Capitalisation (thousands of euros)

31,83124,82829,10525,172

Volume (thousands of shares)

35351515551

Turnover (thousands of euros)

9561,532355107

Company Profile

Founded in Barcelona in 2006, Pangaea Oncology is a medical services company focused on precision oncology, personalized medicine based on genetic analyses to improve survival and quality of life for cancer patients.

The company has two main areas of activity: (i) its clinical care division, the Dr. Rosell Oncology Institute (IOR). Based on the concept of personalized medicine, IOR delivers medical oncology services and related activities at four of the largest hospitals of the Quirónsalud Group in Catalonia; (ii) its Diagnostic and R & D services division, providing diagnostic and in-vitro services to IOR patients and Pangaea's portfolio of pharmaceutical clients, including over 15 multinationals. Pangaea is highly invested in technology, focusing on the development of innovative, proprietary diagnostic techniques (its main commercialized asset is Liquid Biopsy), and development of targeted drugs - to early clinical trial stages - through a strategic agreement with Cancer Research Technology, UK.
 
The synergy between these areas forms the foundation of Pangaea's future growth strategy. 

Relevant Facts and Notices

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.